Limited human safety data
FDA identifies potential immunogenicity associated with aggregation and peptide-related impurities. Its statement specifically concerns injectable routes. It is not a finding that cosmetic GHK-Cu is equally risky. [1]
ORAL / NASAL / INJECTABLE / TOPICAL
Different routes.
Different evidence.
Different risks.
Topical peptide research does not validate oral tablets, nasal sprays or injectable stacks. This review separates catalog identities, direct evidence gaps and FDA safety concerns.
Explore the evidenceFocused research review. Ingredient findings are not finished-product clinical proof.
RESEARCH / EVIDENCE
Same name does not mean same evidence.
A molecule must reach the relevant tissue in an effective and tolerable form. Swallowing it, spraying it into the nose, leaving it on skin and injecting it are different interventions.
On skin
Local cosmetic exposure. Leave-on and rinse-off differ.
Swallowed
Digestion, absorption and metabolism determine exposure.
Intranasal
Mucosal exposure and local tolerability require direct study.
Injected
Sterility, immune responses and systemic risks matter.
Informational safety review only.
This page provides no dosing, injection, reconstitution, nasal-use or sourcing instructions. Inclusion in a catalog is not evidence of clinical benefit or regulatory approval.
RESEARCH / CATALOG
What the catalog says, and what remains unresolved.
| Catalog listing | Identity and route | Evidence boundary |
|---|---|---|
| GHK-Cu Copper Peptide Tablets | Title says tablets; description calls them capsules/oral supplements. | Oral route is clear, dosage form is inconsistent. No matching controlled clinical trial was established in this review. |
| GHK-Cu Nasal Spray | Intranasal GHK-Cu as described by seller. | Claims of rapid absorption, repair or immune benefit are not substantiated by topical cream studies. |
| NAD Nasal Spray | Title says NAD, but description explicitly names nicotinamide mononucleotide (NMN). | Treat molecular identity as unresolved until the current label and lot-specific testing are reconciled. NAD+ and NMN are not synonyms. |
| Glow Peptide | Catalog describes an injectable stack of GHK-Cu, BPC-157 and TB-500. | No trial of this exact stack was located. Do not add up separate ingredient results as if they establish combination efficacy or safety. |
Source: Neurogan product descriptions. These listings are mapped for evidence review, not recommended for use. Concentrations and administration directions are deliberately not reproduced. [4]
Why the NAD/NMN distinction is material
NAD+ is nicotinamide adenine dinucleotide; NMN is nicotinamide mononucleotide, a precursor in its biosynthesis. An oral NMN trial does not establish intranasal NMN bioavailability, nasal tolerability, brain delivery or clinical benefit. Neither an oral NMN paper nor a direct NAD+ study resolves what is in the product. Ask a qualified clinician or pharmacist to reconcile molecular identity, formulation and lot documentation before considering any use.
RESEARCH / GHK
GHK-Cu: keep cosmetic findings on the skin.
The existing topical GHK-Cu review covers cosmetic creams, limited human appearance reports and laboratory models. Those findings do not demonstrate that an oral tablet or nasal spray repairs tissues, improves immunity or reverses aging.
Evidence of copper or peptide movement through isolated skin is not proof of clinically useful exposure after swallowing or nasal administration. Likewise, nutritional copper requirements do not establish efficacy or safety for intact oral GHK-Cu. A label’s peptide mass is not automatically elemental copper mass.
What a route-specific study would need to show
Direct trials should verify chemical identity and stability; measure the intact peptide and relevant metabolites where appropriate; characterize absorption and local tolerability; use a suitable comparator; and assess clinically meaningful outcomes. Adequate follow-up is needed to detect adverse effects. No such matching clinical package for the catalog oral or nasal products was located in this focused review.
Rinse-off GHK-Cu and AHK-Cu are a separate limitation
The catalog shampoo, conditioner and copper-peptide body wash are washed away after short contact. That is not the exposure used in leave-on skin creams or in cells and isolated follicles. AHK-Cu and GHK-Cu are different peptides, and a combined bottle total does not establish the dose of either reaching a hair follicle. Read the AHK-Cu evidence review and the panthenol support review for the relevant boundaries.
RESEARCH / SAFETY
FDA identifies important peptide safety concerns.
Safety remains uncertain
FDA highlights route-dependent immunogenicity concerns, impurities and difficulty characterizing the active ingredient. Limited safety information prevents a confident conclusion that proposed uses would not harm people. [1]
Identity matters
FDA names thymosin beta-4 fragment LKKTETQ, also known as TB-500, and notes potential immune-response and impurity risks plus missing human exposure data for that fragment. [1]
These are potential risks and gaps, not proof that every exposure causes harm. Conversely, missing adverse-event reports do not prove safety. A seller’s “research use,” “not a drug,” testing or facility-registration language does not establish FDA approval of a product.
Regulatory nuance: compounding lists are not approvals
FDA’s safety page includes substances currently in category 2 and substances previously listed whose nominations were withdrawn. Withdrawal is not a finding of safety. The FDA bulks document also distinguishes non-injectable GHK-Cu from injectable GHK-Cu. Its 2026 notes discuss withdrawal clarification and adding non-injectable GHK-Cu back to category 1 pending review. Category 1 consideration does not mean an FDA-approved medicine, established clinical efficacy or blanket permission for any retail product. Regulatory status can change. [3]
RESEARCH / GLOW
The “Glow” stack has no transferable proof.
Combining three experimental peptides creates a new intervention. It can change stability, exposure, impurity burden and immune responses. A cell experiment for one constituent cannot demonstrate whole-stack efficacy, and a small safety study of another does not establish compatibility.
Full-length thymosin beta-4 is not automatically TB-500
Human studies of full-length thymosin beta-4 cannot be assigned to the shorter LKKTETQ fragment. Commercial “TB-500” naming is also not sufficient to verify a peptide sequence. Until exact identity is documented, neither full-length research nor fragment research can be confidently matched to the catalog material. [1]
There is some BPC-157 human reporting, but not stack validation
A 2025 pilot describes two adults previously exposed to intravenous BPC-157. Investigators reported no adverse effects and no changes in the selected laboratory safety markers during the brief study. This was not a blinded controlled trial, not a skin-rejuvenation efficacy trial and not the GHK-Cu/BPC-157/TB-500 stack. Two selected participants cannot establish uncommon harms, repeated-use safety or safety in medically vulnerable groups. No dosing details are reproduced here. [5]
RESEARCH / DECISIONS
A safer way to read the claims.
Ask whether evidence tests the exact molecule, exact formulation and exact route. Ask whether a result is a patient benefit or only a laboratory marker. Ask who evaluated safety, for how long, and whether the product is an approved drug or a compounded preparation.
FDA states that compounded drugs are not FDA-approved and are not reviewed for safety, effectiveness or quality before marketing. Poor compounding can introduce contamination or incorrect strength and cause serious injury. That general principle is not a product-specific finding of contamination in Neurogan products. [2]
Do not self-inject research peptides or improvise nasal use from oral or topical products. A qualified clinician should assess medical need, approved alternatives and risks. Seek urgent medical care for serious symptoms after any product, including breathing difficulty, severe swelling, fainting or signs of infection. Adverse reactions can also be reported through FDA MedWatch.
THE TAKEAWAY
Match the route.
Do not borrow certainty.
Follow the formulation, the route and the comparison actually tested. A plausible mechanism is a reason to study a product, not proof that it works.
SOURCES & FURTHER READING
Read what each finding rests on.
This is a focused review, not a systematic review. Source types and access limits are identified below. Reviewed September 10, 2026.
FDA: bulk substances that may present significant safety risks
Primary regulatory source. Separate entries for injectable GHK-Cu, BPC-157 and thymosin beta-4 fragment (LKKTETQ)/TB-500. Web extraction reviewed; direct download blocked in this environment.
Read source 1 ↗FDA: understanding the risks of compounded drugs
Primary regulatory source. Compounded preparations are not FDA-approved; quality failures can cause serious harm.
Read source 2 ↗FDA: substances nominated under section 503A
Primary regulatory document. 2026 nomination notes distinguish non-injectable GHK-Cu. Nomination/interim categories do not constitute approval.
Read source 3 ↗Catalog descriptions reviewed
Also reviewed: GHK-Cu nasal, NAD nasal and Glow. Seller descriptions identify scope and inconsistencies; not efficacy sources.
Read source 4 ↗Lee & Burgess: intravenous BPC-157 safety pilot, 2025
Primary abstract. Two previously exposed adults; brief, uncontrolled observation. Not a basis for long-term safety or Glow-stack efficacy.
Read source 5 ↗